Gene therapy approaches include gene addition, gene knockdown and gene alteration/correction.
Gene transfer vectors involve the use of non-viral DNA plasmids or are derived from the modification of natural viruses.
Vectors can be designed to express therapeutic protein coding and/or non-coding RNAs. Therapeutic non-coding RNAs include RNAi and microRNAs.
Improvements in gene transfer vector technologies are responsible for early clinical successes in treated inherited blindness, immunodeficiency syndromes and a neurodegenerative disease.
Some technical barriers still exist that limit the wide-scale implementation of gene therapy.
Improved vectors and a better understanding of vector–host interactions are two of the most important goals of gene therapy research.
The advancement in disease prediction using personalized genomics will ultimately influence the use of gene transfer in preventative medical applications.
Improvements in the gene transfer vectors used in therapeutic trials have led to substantial clinical successes in patients with serious genetic conditions, such as immunodeficiency syndromes, blindness and some cancer types. Several barriers need to be overcome before this type of therapy becomes a widely accepted treatment for a broad group of medical diseases. However, recent progress in the field is finally realizing some of the promises made more than 20 years ago, providing optimism for additional successes in the near future.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Multiplexed shRNA-miRs as a candidate for anti HIV-1 therapy: strategies, challenges, and future potential
Journal of Genetic Engineering and Biotechnology Open Access 28 December 2022
Signal Transduction and Targeted Therapy Open Access 23 April 2022
Engineering stem cells to produce exosomes with enhanced bone regeneration effects: an alternative strategy for gene therapy
Journal of Nanobiotechnology Open Access 15 March 2022
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Mingozzi, F. & High, K. A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Rev. Genet. (in the press).
Davidson, B. L. & McCray, P. B. Jr. Current prospects for RNA interference-based therapies. Nature Rev. Genet. (in the press).
Naldini, L. Ex vivo gene transfer and correction for cell-based therapies. Nature Rev. Genet. (in the press).
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. Nature Rev. Genet. 11, 636–646 (2010).
Lu, Q. L. et al. The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Mol. Ther. 19, 9–15 (2011).
Janowski, B. A. & Corey, D. R. Minireview: switching on progesterone receptor expression with duplex RNA. Mol. Endocrinol. 24, 2243–2252 (2010).
Zhou, J. & Rossi, J. J. Aptamer-targeted cell-specific RNA interference. Silence 1, 4 (2010).
Thomas, C. E., Ehrhardt, A. & Kay, M. A. Progress and problems with the use of viral vectors for gene therapy. Nature Rev. Genet. 4, 346–358 (2003).
Kennedy, S., Rettinger, S., Flye, M. W. & Ponder, K. P. Experiments in transgenic mice show that hepatocytes are the source for postnatal liver growth and do not stream. Hepatology 22, 160–168 (1995).
Kay, M. A. et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 262, 117–119 (1993).
Coroadinha, A. S. et al. Production of retroviral vectors: review. Curr. Gene Ther. 10, 456–473 (2010).
Nienhuis, A. W. Development of gene therapy for blood disorders. Blood 111, 4431–4444 (2008).
Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669–672 (2000). This report describes the correction of X-linked SCID in children by gene therapy. It is deemed to be the first established gene therapy cure to be carried out in humans.
Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419 (2003). These authors established that insertional mutagenesis participates in the formation of leukaemia in a subset of patients who were treated for X-linked SCID.
Kohn, D. B. Update on gene therapy for immunodeficiencies. Clin. Immunol. 135, 247–254 (2010).
Boztug, K. et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918–1927 (2010).
Ott, M. G. et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nature Med. 12, 401–409 (2006).
Aiuti, A. et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J. Clin. Invest. 117, 2233–2240 (2007).
Deichmann, A. et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117, 2225–2232 (2007).
Bushman, F. D. Retroviral integration and human gene therapy. J. Clin. Invest. 117, 2083–2086 (2007).
Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318–322 (2010).
Winslow, M. M. et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (in the press).
Cartier, N. et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818–823 (2009).
Bushman, F. et al. Genome-wide analysis of retroviral DNA integration. Nature Rev. Microbiol. 3, 848–858 (2005).
DiGiusto, D. L. et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2, 36ra43 (2010).
Mavilio, F. et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nature Med. 12, 1397–1402 (2006).
Fine, J. D. Inherited epidermolysis bullosa: past, present, and future. Ann. N. Y Acad. Sci. 1194, 213–222 (2010).
Titeux, M., Pendaries, V. & Hovnanian, A. Gene therapy for recessive dystrophic epidermolysis bullosa. Dermatol. Clin. 28, 361–366 (2010).
Trobridge, G. D. Foamy virus vectors for gene transfer. Expert Opin. Biol. Ther. 9, 1427–1436 (2009).
Brunetti-Pierri, N. & Ng, P. Progress towards liver and lung-directed gene therapy with helper-dependent adenoviral vectors. Curr. Gene Ther. 9, 329–340 (2009).
Zaiss, A. K., Machado, H. B. & Herschman, H. R. The influence of innate and pre-existing immunity on adenovirus therapy. J. Cell. Biochem. 108, 778–790 (2009).
Seiler, M. P., Cerullo, V. & Lee, B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr. Gene Ther. 7, 297–305 (2007).
Sheridan, C. Gene therapy finds its niche. Nature Biotech. 29, 121–128 (2011).
Wu, H. & Curiel, D. T. Fiber-modified adenoviruses for targeted gene therapy. Methods Mol. Biol. 434, 113–132 (2008).
McCaffrey, A. P. et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol. Ther. 16, 931–941 (2008).
Lasaro, M. O. & Ertl, H. C. New insights on adenovirus as vaccine vectors. Mol. Ther. 17, 1333–1339 (2009).
Barouch, D. H. Novel adenovirus vector-based vaccines for HIV-1. Curr. Opin. HIV AIDS 5, 386–390 (2010).
Gray, G., Buchbinder, S. & Duerr, A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr. Opin. HIV AIDS 5, 357–361 (2010).
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J. & Melton, D. A. In vivo reprogramming of adult pancreatic exocrine cells to β-cells. Nature 455, 627–632 (2008).
Ferber, S. et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nature Med. 6, 568–572 (2000). The first study to show that diabetes mellitus can be corrected in mouse models of diabetes by using gene transfer to induce cell reprogramming in vivo.
Samson, S. L. & Chan, L. Gene therapy for diabetes: reinventing the islet. Trends Endocrinol. Metab. 17, 92–100 (2006).
Kojima, H. et al. NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nature Med. 9, 596–603 (2003).
Wang, A. Y., Ehrhardt, A., Xu, H. & Kay, M. A. Adenovirus transduction is required for the correction of diabetes using Pdx-1 or Neurogenin-3 in the liver. Mol. Ther. 15, 255–263 (2007).
Cannon, P. & June, C. Chemokine receptor 5 knockout strategies. Curr. Opin. HIV AIDS 6, 74–79 (2011).
Daya, S. & Berns, K. I. Gene therapy using adeno-associated virus vectors. Clin. Microbiol Rev. 21, 583–593 (2008).
Mueller, C. & Flotte, T. R. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 15, 858–863 (2008).
Gao, G., Vandenberghe, L. H. & Wilson, J. M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285–297 (2005).
Choi, V. W., McCarty, D. M. & Samulski, R. J. AAV hybrid serotypes: improved vectors for gene delivery. Curr. Gene Ther. 5, 299–310 (2005).
Hauck, B. & Xiao, W. Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol. 77, 2768–2774 (2003).
Zhong, L. et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl Acad. Sci. USA 105, 7827–7832 (2008).
Li, W. et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16, 1252–1260 (2008).
Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82, 5887–5911 (2008).
Maheshri, N., Koerber, J. T., Kaspar, B. K. & Schaffer, D. V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nature Biotech. 24, 198–204 (2006).
Inagaki, K., Piao, C., Kotchey, N. M., Wu, X. & Nakai, H. Frequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver. J. Virol. 82, 9513–9524 (2008).
Nakai, H. et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75, 6969–6976 (2001).
Deyle, D. R. & Russell, D. W. Adeno-associated virus vector integration. Curr. Opin. Mol. Ther. 11, 442–447 (2009).
Nakai, H. et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J. Virol. 79, 3606–3614 (2005).
Donsante, A. et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477 (2007).
Kay, M. A. AAV vectors and tumorigenicity. Nature Biotech. 25, 1111–1113 (2007).
Maguire, A. M. et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374, 1597–1605 (2009).
Maguire, A. M. et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240–2248 (2008). This study describes improved vision in patients with inherited blindness who were treated using a recombinant AAV vector.
Millington-Ward, S. et al. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol. Ther. 11 Jan 2011 (doi:10.1038/mt.2010.293).
Chadderton, N. et al. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol. Ther. 17, 593–599 (2009).
Hadri, L. et al. SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol. Ther. 18, 1284–1292 (2010).
Hajjar, R. J. et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J. Card. Fail. 14, 355–367 (2008).
Mingozzi, F. et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114, 2077–2086 (2009).
Brantly, M. L. et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl Acad. Sci. USA 106, 16363–16368 (2009).
Manno, C. S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963–2972 (2003).
Kay, M. A. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature Genet. 24, 257–261 (2000).
Miyagoe-Suzuki, Y. & Takeda, S. Gene therapy for muscle disease. Exp. Cell Res. 316, 3087–3092 (2010).
Wang, Z. et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther. 15, 1160–1166 (2007).
DiPrimio, N., McPhee, S. W. & Samulski, R. J. Adeno-associated virus for the treatment of muscle diseases: toward clinical trials. Curr. Opin. Mol. Ther. 12, 553–560 (2010).
Muramatsu, S. et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 18, 1731–1735 (2010).
Fitzsimons, H. L. et al. Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat. J. Gene Med. 12, 385–398 (2010).
Christine, C. W. et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662–1669 (2009).
Eberling, J. L. et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980–1983 (2008).
Hadaczek, P. et al. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol. Ther. 18, 1458–1461 (2010).
Varenika, V. et al. Controlled dissemination of AAV vectors in the primate brain. Prog. Brain Res. 175, 163–172 (2009).
Fiandaca, M. S. et al. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage 47, T27–T35 (2009).
Kells, A. P. et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc. Natl Acad. Sci. USA 106, 2407–2411 (2009).
Snyder, R. O. et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature Med. 5, 64–70 (1999). This report establishes that a single administration of recombinant AAV, by hepatic gene transfer, is safe and therapeutic in both small and large animal models of haemophilia B.
Nichols, T. C. et al. Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B. Haemophilia 16, 19–23 (2010).
Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Med. 12, 342–347 (2006). The first systemic administration of a recombinant AAV vector in humans. This resulted in therapeutic levels of coagulation factor IX that did not persist indefinitely because of an unexpected immune response.
Ponder, K. P. Hemophilia gene therapy: a holy grail found. Mol. Ther. 19, 427–428 (2011).
Pringle, I. A., Hyde, S. C. & Gill, D. R. Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects. Expert Opin. Biol. Ther. 9, 991–1003 (2009).
Park, T. G., Jeong, J. H. & Kim, S. W. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. 58, 467–486 (2006).
Al-Dosari, M. S. & Gao, X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 11, 671–681 (2009).
Hyde, S. C. et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nature Biotech. 26, 549–551 (2008).
Lam, A. P. & Dean, D. A. Progress and prospects: nuclear import of nonviral vectors. Gene Ther. 17, 439–447 (2010).
Dang, J. M. & Leong, K. W. Natural polymers for gene delivery and tissue engineering. Adv. Drug Deliv. Rev. 58, 487–499 (2006).
Herweijer, H. & Wolff, J. A. Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Ther. 14, 99–107 (2007).
Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258–1266 (1999).
Liu, D. & Knapp, J. E. Hydrodynamics-based gene delivery. Curr. Opin. Mol. Ther. 3, 192–197 (2001).
Khorsandi, S. E. et al. Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther. 15, 225–230 (2008).
Wolff, J. A. & Budker, V. The mechanism of naked DNA uptake and expression. Adv. Genet. 54, 3–20 (2005).
Andre, F. & Mir, L. M. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther. 11, S33–S42 (2004).
Chen, Z. Y., He, C. Y., Ehrhardt, A. & Kay, M. A. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol. Ther. 8, 495–500 (2003).
Chen, Z. Y., Riu, E., He, C. Y., Xu, H. & Kay, M. A. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol. Ther. 16, 548–556 (2008).
Kay, M. A., He, C. Y. & Chen, Z. Y. A robust system for production of minicircle DNA vectors. Nature Biotech. 28, 1287–1289 (2010).
Gill, D. R., Pringle, I. A. & Hyde, S. C. Progress and prospects: the design and production of plasmid vectors. Gene Ther. 16, 165–171 (2009). This report summarizes the history and current status of non-viral DNA vectors for use in gene therapy applications.
Ivics, Z. & Izsvak, Z. The expanding universe of transposon technologies for gene and cell engineering. Mob. DNA 1, 25 (2010).
Yant, S. R., Huang, Y., Akache, B. & Kay, M. A. Site-directed transposon integration in human cells. Nucleic Acids Res. 35, e50 (2007).
Hausl, M. A. et al. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol. Ther. 18, 1896–1906 (2010).
Calos, M. P. The phiC31 integrase system for gene therapy. Curr. Gene Ther. 6, 633–645 (2006).
Chalberg, T. W. et al. Integration specificity of phage phiC31 integrase in the human genome. J. Mol. Biol. 357, 28–48 (2006).
Ehrhardt, A., Xu, H., Huang, Z., Engler, J. A. & Kay, M. A. A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol. Ther. 11, 695–706 (2005).
Stone, D. & Lieber, A. New serotypes of adenoviral vectors. Curr. Opin. Mol. Ther. 8, 423–431 (2006).
Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704–712 (2010).
Erles, K., Sebokova, P. & Schlehofer, J. R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59, 406–411 (1999).
Brown, B. D. et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nature Biotech. 25, 1457–1467 (2007).
Brown, B. D., Venneri, M. A., Zingale, A., Sergi Sergi, L. & Naldini, L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nature Med. 12, 585–591 (2006).
Sharma, A., Tandon, M., Bangari, D. S. & Mittal, S. K. Adenoviral vector-based strategies for cancer therapy. Curr. Drug Ther. 4, 117–138 (2009).
Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535–546 (2009).
Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Med. 14, 1264–1270 (2008).
Bollard, C. M. et al. Administration of tumor-specific cytotoxic T lymphocytes engineered to resist TGF-β to patients with EBV-associated lymphomas. Blood Abstr. 116, 560 (2010).
Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
Koski, A. et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol. Ther. 18, 1874–1884 (2010).
Burke, J. M. GM-CSF-armed, replication-competent viruses for cancer. Cytokine Growth Factor Rev. 21, 149–151 (2010).
Kota, J. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005–1017 (2009). The authors show that expressing a single recombinant miRNA from a gene transfer vector inhibits liver cancer.
Goyenvalle, A., Babbs, A., van Ommen, G. J., Garcia, L. & Davies, K. E. Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: promising tool for DMD therapy. Mol. Ther. 17, 1234–1240 (2009).
Franich, N. R. et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol. Ther. 16, 947–956 (2008).
Xia, H. et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nature Med. 10, 816–820 (2004).
McLean, C., Greene, C. M. & McElvaney, N. G. Gene targeted therapeutics for liver disease in α-1 antitrypsin deficiency. Biologics 3, 63–75 (2009).
Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537–541 (2006).
Grimm, D. et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J. Clin. Invest. 120, 3106–3119 (2010).
I would like to thank my previous mentors, past and current trainees, and colleagues for all they have taught me. I apologize for not being able to include many other important approaches and studies owing to a lack of space. This work was funded by grants from the US National Institutes of Health (National Heart, Lung and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute of Allergy and Infectious Diseases) and the Juvenile Diabetes Research Foundation.
The author declares no competing financial interests.
- Zinc finger nucleases
Engineered DNA-binding proteins that produce double-strand breaks at specific sequences. They can be used to correct or induce mutations in genomic DNA.
(RNA interference). The process by which the introduction or expression within cells of dsRNA leads to the sequence-specific cleavage and degradation of a target mRNA and therefore to gene suppression.
- miRNA sponges
Exogenously delivered or expressed non-coding RNAs that bind and inhibit microRNA function in a sequence-specific manner.
- RNA aptamers
Short RNAs selected from large libraries that, owing to their three-dimensional structure, bind to and activate or interfere with protein function and/or direct a macromolecular cargo (for example, small interfering RNAs) into cells via a targeted receptor.
The use of an unnatural or unmatched envelope or capsid protein to package a viral genome.
- Severe combined immune deficiency
(SCID). A lethal disease caused by the lack of B cell and T cell immunity. The disease is caused by a deficiency of one of several genes. It is commonly referred to as the 'bubble boy' disease.
- X-linked adrenoleukodystrophy
An X-linked, neonatal, neuronal de-myelinating disorder.
- RNA decoys
RNA molecules designed to bind and inhibit a biologically active RNA from binding to its target.
- Epidermolysis bullosa
An inherited connective tissue disease resulting in mild to severe (fatal) skin blisters owing to a mutation in collagen or keratin genes.
- Self-limiting toxicity
A toxicity reaction that resolves without intervention.
- Ornithine transcarbamylase deficiency
Ornithine transcarbamylase is an enzyme in the urea cycle that is crucial for the conversion of ammonia to urea. Deficiency results in high blood ammonia levels, mental retardation and possible death.
- Helper-dependent packaging system
A means of packaging adenoviral vectors that are devoid of all their genes. The pared-down adenoviral genome is expressed from a helper adenovirus that lacks a packaging signal; this permits the vector but not the helper virus to be packaged.
- Leber's congenital amaurosis
An inherited and incurable blindness disorder.
- Ambulatory vision
The degree of vision that allows one to see enough to get around a room without bumping into objects.
- Image-guided vector placement
The use of imaging technologies, such as real-time magnetic resonance imaging, to pinpoint the delivery of a vector through a catheter.
- Minicircle DNAs
Expression cassettes that are devoid of the plasmid DNA backbone.
- Sleeping Beauty
An ancient inactive transposon isolated from salmon. The transposase was reactivated by introducing various mutations.
About this article
Cite this article
Kay, M. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 12, 316–328 (2011). https://doi.org/10.1038/nrg2971
This article is cited by
Molecular Biotechnology (2023)
Engineering stem cells to produce exosomes with enhanced bone regeneration effects: an alternative strategy for gene therapy
Journal of Nanobiotechnology (2022)
Multiplexed shRNA-miRs as a candidate for anti HIV-1 therapy: strategies, challenges, and future potential
Journal of Genetic Engineering and Biotechnology (2022)
Molecular Psychiatry (2022)
Nature Reviews Methods Primers (2022)